We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ZoBio, Domainex Partner to support FORMA Therapeutics’ Drug Discovery Programs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

The goal of the collaboration is to use ZoBio’s expertise in protein nuclear magnetic resonance (NMR) to elucidate the molecular basis for compound-target interaction, to complement ongoing X-ray crystallography approaches. NMR is currently the only alternative to crystallography capable of elucidating atomic resolution, 3D structural information. Under the agreement, ZoBio will design and express protein variants suitable for structural studies, to support FORMA’s oncology drug discovery research.

In addition, Domainex will apply its Combinatorial Domain Hunting technology to generate suitable protein variants for a selection of particularly challenging targets, not previously amenable to structural studies. Successful targets from the joint ZoBio/Domainex effort will be used for subsequent NMR structural biology studies.

Gregg Siegal, CEO of ZoBio said “We are proud that FORMA, a company with tremendous success in broadly exploring the druggability of target families, has selected ZoBio as a partner. We are excited to provide structural insight where it has not previously been possible.”

Eddy Littler, CEO of Domainex said “We are excited to be working alongside ZoBio to support FORMA in its pursuit of novel cancer drugs.  ZoBio and Domainex’s combined technology offering enables previously intractable, but hugely promising drug targets to be tackled; paving the way to a raft of potential new and efficacious oncology drugs.”

Advertisement